Login / Signup

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy.

Tae Wook KangHyun Chul Chung
Published in: Therapeutic advances in urology (2020)
A combination of tamsulosin and mirabegron might improve the QoL of patients presenting with persistent storage symptoms after tamsulosin monotherapy. Better QoL due to mirabegron compared with solifenacin could be associated with fewer adverse effects, such as dry mouth and constipation.
Keyphrases
  • benign prostatic hyperplasia
  • lower urinary tract symptoms
  • combination therapy
  • open label
  • sleep quality
  • randomized controlled trial
  • clinical trial
  • irritable bowel syndrome
  • replacement therapy